GlassScriptPhysician profile
Jessica S Matthews
NPI 1831850130
$18,893.24
in general payments reported to CMS, 2019-2025
47 companies · $1,905 in 2025
The $1,905 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,197 · 2023: $10K · 2024: $3,299 · 2025: $1,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,771 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,039 · Travel and Lodging: $1,818 · Consulting Fee: $990 · Education: $79.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,770.70 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,038.66 |
| Travel and Lodging | $1,817.78 |
| Consulting Fee | $990.00 |
| Education | $79.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $4,130.08 | 2022-2025 | Austedo, Austedo Xr, Ajovy |
| Mdd US Operations, LLC | $3,429.70 | 2023-2025 | Gocovri, Apokyn, Gocovri |
| Abbvie INC. | $946.72 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $882.89 | 2022-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $772.66 | 2022-2025 | Nuplazid |
| Sk Life Science, INC. | $722.26 | 2022-2025 | Xcopri |
| Biogen, INC. | $647.40 | 2022-2025 | Vumerity, Tysabri |
| Lundbeck LLC | $609.18 | 2022-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $600.29 | 2022-2025 | Ultomiris |
| Neurelis, INC. | $576.81 | 2022-2025 | Valtoco |
| Pfizer INC. | $568.64 | 2022-2025 | |
| Emd Serono, INC. | $565.11 | 2022-2024 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $416.74 | 2022-2025 | |
| Ucb, INC. | $318.49 | 2022-2025 | Briviact, Cimzia |
| Csl Behring | $285.91 | 2022-2024 | Hizentra |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $285.57 | 2022-2025 | Evenity, Aimovig |
| Amneal Pharmaceuticals LLC | $271.10 | 2022-2024 | Crexont, Rytary |
| Lilly USA, LLC | $244.87 | 2022-2025 | Zepbound, Emgality, Reyvow |
| Astrazeneca Pharmaceuticals LP | $208.35 | 2023-2024 | Farxiga |
| Upsher-Smith Laboratories LLC | $203.81 | 2022-2023 | |
| Nevro Corp. | $195.61 | 2022-2023 | Senza |
| Janssen Pharmaceuticals, INC | $189.49 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $188.71 | 2022 | |
| Corium, LLC | $155.98 | 2023 | Adlarity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $140.49 | 2025 | Caplyta |
| Eisai INC. | $118.91 | 2022-2024 | |
| Livanova USA, INC. | $114.92 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Impel Pharmaceuticals INC. | $99.23 | 2023 | Trudhesa |
| Dexcom, INC. | $97.56 | 2023 | Dexcom G7 Gss (161) |
| Springworks Therapeutics, INC. | $94.55 | 2025 | Gomekli |
| Glaxosmithkline, LLC. | $92.73 | 2023 | Arexvy |
| Otsuka America Pharmaceutical, INC. | $89.63 | 2023-2024 | Rexulti |
| Viiv Healthcare Company | $82.86 | 2025 | Apretude |
| Tanabe Pharma America, INC. | $68.52 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $63.85 | 2025 | |
| Argenx US, INC. | $62.60 | 2022-2023 | Vyvgart |
| Averitas Pharma INC. | $54.12 | 2024 | Qutenza |
| Banner Life Sciences, LLC | $50.64 | 2022-2023 | |
| Novo Nordisk INC | $50.29 | 2022 | |
| Tg Therapeutics, INC. | $37.51 | 2025 | |
| Supernus Pharmaceuticals, INC. | $36.43 | 2022 | |
| Genentech USA, INC. | $34.69 | 2024 | Ocrevus, Ocrevus Zunovo |
| Catalyst Pharmaceuticals, INC. | $22.71 | 2024 | |
| Celgene Corporation | $17.71 | 2024 | Zeposia |
| Avion Pharmaceuticals | $17.55 | 2022 | |
| Metacel Pharmaceuticals LLC | $16.64 | 2024 | Ozobax |
| Merck Sharp & Dohme LLC | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.